MR epectroscopic imaging may help better diagnose, treat multiple sclerosis

MR epectroscopic imaging may help better diagnose, treat multiple sclerosis

Magnetic resonance spectroscopic imaging (MRSI) performed at 7.0 T (7.0-T MRSI) could visualize pathologic findings of multiple sclerosis (MS) which were not detectable using T1- or T2-weighted magnetic resonance imaging (MRI), according to study findings published in Radiology.

Focal white matter lesions are the most detectable feature for patients with MS, however, these lesions fail to fully explain the topographical origin and severity of many clinical symptoms among patients with MS. Recent advances in 7.0-T MRSI technology have the potential to allow for more comprehensive visualization of clinical disease features.

Patients (n=65) with MS and healthy control individuals (n=20) were recruited at the Medical University of Vienna in Austria and Jessenius Faculty of Medicine in Martin in Slovakia between 2016 and 2017. Patients underwent three-dimensional T1-weighted MRI, three-dimensional T2-weighted MRI using fluid-attenuated inversion recovery, and free-induction decay MRSI at 7.0 T. Using the Expanded Disability Status Scale (EDSS), patients were stratified into low (EDSS 0-1; n=26), intermediate (EDSS 1.5-3; n=27), and advanced (EDSS ³3.5; n=12) disability groups.

The MS cohort and individuals in the control cohort were comprised 34 and 11 women and 31 and 9 men and were aged mean 34±9 and 32±7 years, respectively. Among the patient group, 61 had relapsing-remitting MS and 4 secondary progressive MS.

Normal-appearing white matter (NAWM) in the centrum semiovale was the most different between control individuals (mean, myo-inositol to N-acetylaspartate [mI/NAA] ratio, 0.56; myo-inositol to total creatine [mI/tCr] ratio, 0.78) and the patients with EDSS 0-1 (mean, mI/NAA, 0.64; P =.03 mI/tCr, 0.86; P =.02), EDSS 1.5-3 (mean, mI/NAA, 0.76; P <.001 mI/tCr, 0.95; P <.001), and ³3.5 (mean, mI/NAA, 0.75; P <.001 mI/tCr, 0.94; P=.001)

Frontal cortical gray matter (CGM) was observed to be less affected than NAWM overall, however, still differed between control individuals in patients in the cingulate cortex.

Neurometabolite alterations were also more pronounced in white matter lesions. The greatest difference was observed for mI/NAA among patients with EDSS 0-1, in which they had higher ratios for lesions (mean, 0.99) than NAWM (mean, 0.63; P <.001). A similar pattern was observed for mI/tCr among the same group (mean, 1.07 vs 0.83; P=.002), respectively.

Greater mI/NAA ratio was correlated with EDSS score in the centrum semiovale (r, 0.47; P <.001), frontal CGM (r, 0.37; P=.004), parietal NAWM (r, 0.43; P=.002), and frontal NAWM (r, 0.34; P=.01). Also, higher mI/tCr was associated with a higher EDDS score in the NAWM of centrum semiovale (r, 0.35; P=.007). The ratio between N-acetylaspartate and total creatine was negatively correlated with EDSS score in the frontal CGM (r, -0.28; P=.04) and cingulate cortex (r, -0.32; P=.02), and also the ratio between total choline to total creatine in white matter lesions (r, -0.38; P <.001).

This study was limited by the area assessed by the 7.0-T MRSI which was a single two-dimensional section measuring 8 mm.

“MR spectroscopic imaging at 7.0 T allowed in vivo visualization of multiple sclerosis pathologic findings not visible at T1- or T2-weighted MRI,” the researchers concluded.

Disclosure: Multiple authors declared affiliations with industry. Please refer to the original article for a full list of disclosures.

Reference
Heckova E, Dal-Bianco A, Stasser B, et al. Extensive Brain Pathologic Alterations Detected with 7.0-T MR Spectroscopic Imaging Associated with Disability in Multiple Sclerosis. Radiology. Published online January 4, 2022. doi:10.1148/radiol.210614

Written by: Jessica Nye, PhD

NeurologyAdvisor

CMSC Disclaimer

The industry news information and articles are for informational purposes only, and are not intended to represent any trends, partnerships, commitments, or research of the Consortium of MS Centers or any of it's members in any way whatsoever, nor should any party be libel in any way to the reader or to any other person, firm or corporation reading this industry news section. Although the CMSC site includes links providing direct access to other Internet sites, CMSC takes no responsibility for the content or information contained on those other sites, and does not exert any editorial or other control over those other sites. CMSC is providing information and services on the Internet as a benefit and service in furtherance of CMSC's nonprofit and tax-exempt status. CMSC makes no representations about the suitability of this information and these services for any purpose.

Elizabeth Porco

Comments are closed.

CMSC provides leadership in clinical research and education; develops vehicles to share information and knowledge among members; disseminates information to the health care community and to persons affected by MS.

Contact Us
Contact Us
I have a question about
First
Last

Feel Free To contact Us
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Nam molestie, tellus id pellen tesque feugiat, sem sem cursus orci, a placerat ante ante nec massa. consectetuer adipiscing elit.

+1-222-333-4444

New York, NY 10123 USA

Mon - Sat 9:00 AM